Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors

(2013) Don W. Coulter et al.   ANTI-CANCER DRUGS

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer

(2012) Hong Jian Xie et al.   PLoS One

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas

(2012) Michael J. Kluk et al.   PLoS One

Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells

(2011) Roser Francisco et al.   CANCER LETTERS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

(2011) Jia-Jia Huang et al.   HUMAN PATHOLOGY

Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines

(2011) J. Fu et al.   NEURO-ONCOLOGY

Signal Transduction Inhibitor Therapy for Lymphoma

(2011) T. E. Witzig et al.   Hematology-American Society of Hematology Education Program

Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer

(2010) Kevin Dalby et al.   Autophagy

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

(2010) Yuan-Ling Liu et al.   Autophagy

Beclin 1 expression: A predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type

(2010) Jia-Jia Huang et al.   Autophagy

Novel therapeutic agents for B-cell lymphoma: developing rational combinations

(2010) C. B. Reeder et al.   BLOOD

The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma

(2010) Suzanne M. Cloonan et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted therapy in lymphoma

(2010) Patrick B Johnston et al.   Journal of Hematology & Oncology

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab

(2009) Julie Turzanski et al.   BRITISH JOURNAL OF HAEMATOLOGY

MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E-Binding Protein 1-Mediated Inhibition of Autophagy

(2009) B. S. Balakumaran et al.   CANCER RESEARCH

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

(2009) Regan M. Memmott et al.   CELLULAR SIGNALLING

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

(2009) Shundong Cang et al.   Journal of Hematology & Oncology

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

(2009) RuiRong Yuan et al.   Journal of Hematology & Oncology

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

(2009) Q-L Zhang et al.   LEUKEMIA

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

(2008) Victor Y. Yazbeck et al.   EXPERIMENTAL HEMATOLOGY

Autophagy fights disease through cellular self-digestion

(2008) Noboru Mizushima et al.   NATURE